医薬品開発業務受託機関の市場規模、シェア、成長分析、タイプ別、治療領域別、エンドユーザー別、地域別 - 産業予測 2025～2032年

医薬品開発業務受託機関の世界市場規模は2023年に613億米ドルと評価され、2024年の663億9,000万米ドルから2032年には1,256億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.3％で成長する見通しです。

医薬品開発業務受託機関（CRO）市場は、ヘルスケアにおけるアウトソーシングの増加傾向や世界の製造コストの高騰を背景に、大きな成長が見込まれています。医療研究への投資と臨床試験の増加はCROのビジネスチャンスを拡大すると予想されます。医薬品開発は複雑であるため、CROへの需要はさらに高まり、医療提供者は収益性を高めながらコストを削減できるようになります。さらに、新興市場における良好な規制環境は、事業拡大の新たな道筋を示しています。しかし、知的財産権の問題、製薬企業への依存、CRO間の激しい競争といった課題に直面しています。全体として、チャンスは豊富にあるもの、利害関係者は市場の有望な可能性を生かすためにこれらの抑制要因をうまく乗り切らなければならないです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術分析

医薬品開発業務受託機関市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 創薬
  • ターゲット検証
  • リード識別
  • リード最適化
  • その他
• 前臨床
• 臨床
  • フェーズI試験サービス
  • フェーズII試験サービス
  • フェーズIII試験サービス
  • フェーズIV試験サービス
• その他

医薬品開発業務受託機関市場規模：治療領域別& CAGR（2025-2032）

• 市場概要
• 腫瘍学
• 心臓病学
• 感染症
• 神経学
• 免疫疾患
• 消化器内科・肝臓病学
• その他

医薬品開発業務受託機関市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 製薬およびバイオテクノロジー企業
• 医療機器企業
• その他

医薬品開発業務受託機関市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• IQVIA（USA）
• ICON plc（Ireland）
• Charles River Laboratories（USA）
• Medpace（USA）
• Fortrea（USA）
• Parexel（USA）
• Syneos Health（USA）
• Thermo Fisher Scientific（USA）
• PPD Inc.（USA）
• Labcorp Drug Development（USA）
• Eurofins Scientific（France）
• SGS SA（Switzerland）
• PSI CRO AG（Switzerland）
• Novotech（Australia）
• KCR S.A.（Poland）
• Linical Co., Ltd.（Japan）
• Pharmaron（China）
• WuXi AppTec（China）
• WuXi Biologics（China）
• Tigermed（China）

結論と提言

Global Contract Research Organization Market size was valued at USD 61.3 billion in 2023 and is poised to grow from USD 66.39 billion in 2024 to USD 125.64 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The contract research organization (CRO) market is poised for significant growth driven by the increasing trend of outsourcing in healthcare and surging global manufacturing costs. Investments in medical research and a rise in clinical trials are anticipated to enhance business opportunities for CROs. The intricate nature of drug development further fuels demand for these organizations, enabling healthcare providers to reduce costs while enhancing profitability. Additionally, favorable regulatory environments in emerging markets present new avenues for expansion. However, the market faces challenges from intellectual property concerns, reliance on pharmaceutical firms, and intense competition among CROs. Overall, while opportunities abound, stakeholders must navigate these restraints to capitalize on the market's promising potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contract Research Organization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contract Research Organization Market Segments Analysis

Global Contract Research Organization Market is segmented by Type, Therapeutic Area, End-User and region. Based on Type, the market is segmented into Drug Discovery, Pre-Clinical, Clinical and Others. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Infectious Disease, Neurology, Immunological Disorders, Gastroenterology and Hepatology and Others. Based on End-User, the market is segmented into Pharmaceutical and Biotechnological Companies, Medical Device Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Contract Research Organization Market

The global contract research organization (CRO) market is significantly driven by the rising trend of outsourcing within the healthcare sector, especially as the demands on healthcare systems continue to escalate. Pharmaceutical and biotechnology companies are increasingly turning to CROs for their clinical trials, drug development, and regulatory services. This strategic shift allows these companies to lower expenses, tap into specialized knowledge, and accelerate the process of bringing new products to market. As a result, the reliance on CROs is intensifying, fostering growth within the industry and enhancing collaborative opportunities between pharmaceutical firms and research organizations.

Restraints in the Global Contract Research Organization Market

As intellectual property rights tighten in the pharmaceutical and biotech sectors, companies may grow increasingly apprehensive about the security of their proprietary information when outsourcing to contract research organizations (CROs). This heightened concern over the protection of intellectual property could pose a significant challenge to the growth of the global CRO market. If companies perceive the risk of intellectual property theft or misuse to be too high, they may hesitate to engage with CROs, which can ultimately hinder market expansion and limit collaboration in research and development efforts within these industries in the foreseeable future.

Market Trends of the Global Contract Research Organization Market

The Global Contract Research Organization (CRO) market is witnessing a significant trend toward the integration of Artificial Intelligence (AI) and machine learning technologies. These advancements are revolutionizing clinical trial processes by enhancing trial design, optimizing patient recruitment, and streamlining data analysis, resulting in improved efficiency and accuracy. The increased adoption of AI enables CROs to automate various business functions, reducing operational costs and expediting project timelines. This technological shift is not only transforming how CROs operate but also enhancing the drug development pipeline, ultimately driving growth in the market as stakeholders seek innovative solutions for complex clinical challenges.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Contract Research Organization Market Size by Type & CAGR (2025-2032)

• Market Overview
• Drug Discovery
  • Target Validation
  • Lead Identification
  • Lead Optimization
  • Others
• Pre-Clinical
• Clinical
  • Phase I Trial Services
  • Phase II Trial Services
  • Phase III Trial Services
  • Phase IV Trial Services
• Others

Global Contract Research Organization Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Cardiology
• Infectious Disease
• Neurology
• Immunological Disorders
• Gastroenterology and Hepatology
• Others

Global Contract Research Organization Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical and Biotechnological Companies
• Medical Device Companies
• Others

Global Contract Research Organization Market Size & CAGR (2025-2032)

• North America (Type, Therapeutic Area, End-User)
  • US
  • Canada
• Europe (Type, Therapeutic Area, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Area, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Area, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Area, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• IQVIA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fortrea (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PSI CRO AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novotech (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KCR S.A. (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Linical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tigermed (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations